Tablets with hardness and abrasion resistance can be manufactured: OSDrC technology and contract formulation development.
Introduction to the improvement of moldability using OSDrC technology! Even active ingredients with poor molding properties can be tabletized.
The "OSDrC" technology, with its variable double-structure design, allows for precise and flexible control of the inner core, enabling the production of high-quality core tablets compared to conventional methods, as well as facilitating the development of various new dosage forms. By localizing the active ingredient in the inner core and using a highly moldable powder for the outer layer, it is possible to create tablets even from active ingredients that have poor moldability. 【Features】 ■ The increase in tablet size can be minimized even for OD tablets, which tend to have a larger powder volume. ■ The hardness and disintegration properties of the tablets can be adjusted according to the intended purpose. ■ It is possible to combine with other OSDrC technologies, such as OD tablets that do not expose the inner core when split. * Data comparing the wear resistance of OSDrC tablets produced using OSDrC technology with tablets physically mixed with active ingredients that have poor moldability can be viewed by downloading from the special website below. * For more details on OSDrC technology, please refer to the OSDrC main brochure available on the special website below or feel free to contact us.
Inquire About This Product
basic information
Please feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
Please feel free to contact us.
catalog(1)
Download All CatalogsCompany information
Sanwa Chemical Research Institute, as a member of the Suzuken Group focused on health creation, provides services aimed at improving the quality of life (QOL) for people who wish for better health, centered around its two main businesses: "pharmaceuticals" and "diagnostic drugs." In the "pharmaceuticals business," we are steadily building a track record with a focus on new drugs in the areas of diabetes and kidney/dialysis-related fields. In the "diagnostic drugs business," we are continuously developing and launching self-blood glucose meters, sensors, and diagnostic drugs for infectious diseases. Furthermore, by adding two more businesses— the "OSDrC (Osudrack) business" utilizing innovative formulation technology and the "contract manufacturing business" with advanced quality control systems— Sanwa Chemical Research Institute continues to evolve further.